(Note: This is a blank-check company or SPAC IPO of common stock – and NOT units. Most SPAC IPOs are unit offerings.)

We intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare industry, with an emphasis on the biotechnology sector where our management has extensive investment experience.

Our sponsor is an affiliate of RA Capital, a leading life sciences focused investment firm with over $7 billion of regulatory assets under management as of Dec. 31, 2020. Since its launch in 2002, RA Capital has focused exclusively on the healthcare industry. Peter Kolchinsky, PhD, our founding Chairman and Chief Executive Officer, founded RA Capital, where he is a Managing Partner. Matthew Hammond, PhD, our founding Chief Investment Officer and Director, and Tess Cameron, our founding Chief Financial Officer and Director, are Principals on the investment team at RA Capital.

(Note: Research Alliance Corp. II priced its SPAC IPO on March 17, 2021, in sync with the terms in its prospectus: 13 million shares of Class A common stock at $10 each to raise $130 million.)